News

NOS2 Exhibits Therapeutic Potential in Mouse Study

Suppressing the production of an enzyme called nitric oxide synthase 2 (NOS2) led to reductions in alpha-synuclein-related abnormalities and neuroinflammation in a mouse model of Parkinson’s disease, a new study reports. “Our data indicate that NOS2 may be a therapeutic target for modulating [Parkinson’s disease] in the brain,” the…

FDA Lifts Hold on IkT-148009; Trial to Resume Soon

The U.S. Food and Drug Administration (FDA) has lifted its full clinical hold on IkT-148009, Inhibikase Therapeutics’ investigational oral therapy for Parkinson’s disease. The agency had placed a hold on all clinical trials of IkT-158009 in December, just a few months after Inhibikase had begun dosing Parkinson’s patients in a …